Please assess the completion status of the following clinical trial:

Trial Title: A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2, and a body weight ≥ 45 and ≤ 95 kg at the screening visit.~* The subject is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, vital signs, an ECG, and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests at screening.~Exclusion Criteria:~* The subject fulfils the diagnostic criteria for a primary headache disorder, or has a first degree relative with a primary headache disorder, according to the International Headache Society (IHS) International Classification of Headache Disorders 3rd edition (ICHD-3), except tension-type headache.~* The subject has or has had tension-type headache more than once per month on average during the 6 months prior to the screening visit.~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo + saline (Type: EXPERIMENTAL): Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
- Placebo + VIP and PACAP (Type: EXPERIMENTAL): Placebo, 0.9% normal saline, single dose intravenous infusion over 30 minutes
- Lu AG09222 + VIP and PACAP (Type: EXPERIMENTAL): Lu AG09222, single dose intravenous infusion over 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).